activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 23, 1996.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. Collective Bancorp, Inc., Cologne, New Jersey; to become a bank holding company by acquiring 100 percent of the voting shares of Continental Bancorporation, Laurel Springs, New Jersey, and thereby indirectly acquire Continental Bank of New Jersey, Laurel Springs, New Jersey.

In connection with this application Collective Bancorp, Inc., has applied to acquire Collective Bank, Egg Harbor, New Jersey, and thereby engage in operating a savings association pursuant to § 225.25(b)(9) of the Board's Regulation Y; Collective Mortgage Services, Inc., Egg Harbor, New Jersey, and thereby engage in making and servicing loans pursuant to § 225.25(b)(1) of the Board's Regulation Y; Collective Financial Services, Egg Harbor, New Jersey, and thereby engage in securities brokerage activities and insurance agency activities in a town of less than 5,000 and underwriting activities pursuant to §§ 225.25(b)(15) and 225.25(b)(8)(iii) & (i) of the Board's Regulation Y.

B. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. Norwest Corporation, Minneapolis, Minnesota; to acquire 100 percent of the voting shares of American Bank Moorhead, Moorhead, Minnesota.

Board of Governors of the Federal Reserve System, July 25. 1996.

Jennifer J. Johnson

Deputy Secretary of the Board

[FR Doc. 96–19352 Filed 7–30–96; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Notice of Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rate determined from the ''Schedule of Certified Interest Rates with Range of Maturities.'' This rate may be revised quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the Federal Register.

The Secretary of the Treasury has certified a rate of 13½% for the quarter ended June 30, 1996. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: July 23, 1996.

George Strader,

Deputy Assistant Secretary, Finance.

[FR Doc. 96–19491 Filed 7–30–96; 8:45 am]

BILLING CODE 4150–04–M

Agency for Health Care Policy and Research

Health Care Policy and Research Special Emphasis Panel Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of August 1996:

Name: Health Care Policy and Research Special Emphasis Panel.

Date and Time: August 20, 1996, 8 a.m.

Place: Key Bridge Marriott, 1401 Lee Highway, Conference Room TBA, Arlington, Virginia 22209.

Open August 20, 8 a.m. to 8:15 a.m.

Closed for remainder of meeting.

Purpose: This Panel is charged with conducting the initial review of grant applications proposing to design and conduct collaborative, multisite, randomized controlled trials to compare the effectiveness and outcomes of hysterectomy to those of other common treatments for non-cancerous uterine conditions.

Agenda: The open session of the meeting on August 20, from 8 a.m. to 8:15 a.m., will be devoted to a business meeting covering administrative matters. During the closed session, the panel will be reviewing and discussing grant applications dealing with health services research issues. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C. 552b(c)(6), the Administrator, AHCPR, has made a formal determination that this latter session will be closed because the discussions are likely to include personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Linda Blankenbaker, Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594–1437 x1603.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: July 25, 1996.

Clifton R. Gaus,

Administrator.

[FR Doc. 96–19506 Filed 7–30–96; 8:45 am]

BILLING CODE 4160–90–M

Food and Drug Administration

[Docket No. 96M–0254]

CIBA Vision Corp.; Premarket Approval of SOLO-care brand MULTI-PURPOSE SOLUTION

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by CIBA Vision Corp., Duluth, GA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of SOLO-care brand MULTI-PURPOSE SOLUTION. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of April 25, 1996, of the approval of the application.

DATES: Petitions for administrative review by August 30, 1996.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James F. Saviola, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–1744.

SUPPLEMENTARY INFORMATION: On December 22, 1994, CIBA Vision Corp., Duluth, GA 30136–1518, submitted to CDRH an application for premarket approval of the SOLO-care brand MULTI-PURPOSE SOLUTION. The device is a cleaning, rinsing, disinfecting, and storing solution and is indicated for cleaning, rinsing, disinfecting, and storing soft (hydrophilic) contact lenses and for dissolving enzyme tablets.

In accordance with the provisions of section 515(c)(2) of the act (21 U.S.C.

360e(c)(2)) as amended by the Safe Medical Devices Act of 1990, this premarket approval application (PMA) was not referred to the Ophthalmic Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, for review and recommendation because the information in the PMA substantially duplicates information previously reviewed by this panel.

On April 25, 1996, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before August 30, 1996, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: June 5, 1996.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 96–19507 Filed 7–30–96; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Availability of an Environmental Assessment and Receipt of an Application for an Incidental Take Permit for Pacific Gas and Electric Company's Blackhawk Distribution Feeder Main Natural Gas Pipeline, Contra Costa County, CA

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of availability.

SUMMARY: This notice advises that the Pacific Gas and Electric Company has applied to the U.S. Fish and Wildlife Service (Service) for an incidental take permit pursuant to of the Endangered Species Act of 1973, as amended (Act). The application has been assigned permit number PRT–817075. The proposed permit would authorize the incidental take of the federally threatened California red-legged frog (*Rana aurora draytonii*) and/or its habitat during the installation and operation of a natural gas distribution pipeline. The permit would be in effect for three years.

The Service also announces the availability of an environmental assessment for the incidental take permit application, which includes the proposed Habitat Conservation Plan (HCP) fully describing the proposed project and mitigation, and the accompanying Implementing Agreement. This notice is provided pursuant to section 10(a) of the Act and National Environmental Policy Act regulations (40 CFR 1506.6). All comments, including names and addresses, received will become part of the official administrative record and may be made available to the public.

DATES: Written comments on the permit application, environmental assessment and Implementing Agreement should be received on or before August 30, 1996.

ADDRESSES: Comments regarding the application or adequacy of the environmental assessment and Implementing Agreement should be addressed to, U.S. Fish and Wildlife Service, Sacramento Field Office, 3310 El Camino, Suite 130, Sacramento, California 95821–6340. Please refer to permit number PRT–817075 when submitting comments. Individuals wishing copies of the application, environmental assessment or Implementing Agreement for review should immediately contact the above office. Documents will also be available for public inspection, by appointment, during normal business hours at the above address.

FOR FURTHER INFORMATION CONTACT: Mr. Michael Horton or Ms. Tiki Baron, Sacramento Field Office, 916–979–2725.

SUPPLEMENTARY INFORMATION: Section 9 of the Act prohibits the ''taking'' of a species listed as threatened or endangered. However, the Service, under limited circumstances, may issue permits to take listed species incidental to, and not the purpose of, otherwise lawful activities. Regulations governing permits for threatened species are promulgated at 50 CFR 17.32.

Background

Pacific Gas and Electric Company proposes to install and operate a 4-mile-long buried natural gas pipeline within a 50-foot-wide right-of-way in the vicinity of San Ramon, Contra Costa County, California. The site is located east and south of San Ramon, California. Pacific Gas and Electric Company seeks coverage for the temporary disturbance of habitat and potential direct take of the California red-legged frog on approximately 5 acres of the project site. To compensate for project impacts, Pacific Gas and Electric Company will develop and implement a plan to acquire, enhance, maintain, restore and/or create and monitor approximately 10 acres of suitable California red-legged frog habitat (two acres of compensation habitat for every one acre of habitat disturbed) within the San Francisco Bay/Suisun Bay watershed. In addition, the approximately 5 acres of temporarily disturbed habitat would be restored to suitable California red-legged frog habitat. Other measures are specified in the Habitat Conservation Plan to minimize the potential for take during installation activities.

The environmental assessment considers the environmental consequences of four alternatives. The no project alternative would result in no